EPR-Technologies Outlined Goals During Its Crowdfunding Campaign

Announcement

EPR-Technologies promoted its goals during an equity-crowdfunding campaign for emergency-preservation research. The Arizona company described technology intended to cool the body rapidly in a tightly controlled medical setting after catastrophic blood loss or cardiac arrest. Its public campaign record confirms a 2022 fundraising effort and explains that the proposed product was still in development rather than an established, generally available treatment.

The original release connected the venture to research at the University of Pittsburgh's Safar Center for Resuscitation Research and discussed patents and specialized equipment. Claims that rapid cooling could extend the time available for resuscitation were a research hypothesis and company objective, not a promise that the technique would save a given patient. Clinical trial authorization and commercial approval are different milestones and should not be conflated.

The old campaign terms and targets are not a current offer of securities. Interested readers should use up-to-date trial registries, regulatory records, and company filings for current status. Investors face substantial scientific, regulatory, financing, and liquidity risks, while patients should rely on emergency clinicians for treatment decisions.